Spero Therapeutics to Present at Upcoming Investor Conference

Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, announced that Ankit Mahadevia, M.D., will present at the 24th Annual H.C. Wainwright Global Investment Conference from September 12-14, 2022. The presentation is scheduled for September 12 at 3:30 PM ET at Lotte New York Palace Hotel. Spero focuses on treatments for rare diseases and multi-drug resistant infections, with key products including SPR720 for rare pulmonary disease and SPR206 for Gram-negative infections. Webcasts of the presentation will be available on their website after the event.

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 24^th Annual H.C. Wainwright Global Investment Conference, which is taking place September 12-14, 2022. Details for the presentation are as follows:

24^th Annual H.C. Wainwright Global Investment Conference
Conference Location: Lotte New York Palace Hotel, New York, NY.
Presentation Format: Corporate Presentation
Presentation Date & Time: Monday, September 12, 2022, at 3:30 PM ET
Webcast link: https://journey.ct.events/view/d64265b3-acb7-4c51-bb98-b85beb432e2b

Webcasts of the presentations may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and Media” tab. A replay of the presentations will be available on the website following the conclusion of the event.

About Spero Therapeutics
Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

• Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
  
  
• Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting.
  
  
• Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.
  

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and Strategic Finance
IR@sperotherapeutics.com
(617) 798-4039

Media Inquiries: media@sperotherapeutics.com

FAQ

When will Spero Therapeutics present at the H.C. Wainwright Global Investment Conference?

Spero Therapeutics will present on September 12, 2022, at 3:30 PM ET.

What is the focus of Spero Therapeutics (SPRO)?

Spero Therapeutics focuses on developing treatments for rare diseases and multi-drug resistant bacterial infections.

Where is the H.C. Wainwright Global Investment Conference held?

The conference is being held at the Lotte New York Palace Hotel in New York, NY.

What products is Spero Therapeutics currently developing?

Spero is developing SPR720 for rare pulmonary disease and SPR206 for multi-drug resistant Gram-negative infections.

Will Spero Therapeutics provide a webcast of their presentation?

Yes, a webcast of the presentation will be available on Spero Therapeutics' website after the event.